Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Next Generation Sequencing Facilitates Quantitative Analysis of Transcriptomes for advanced gastric cancer with different ferroptosis-related-scores

ABSTRACT: Next Generation Sequencing Facilitates Quantitative Analysis of Transcriptomes for advanced gastric cancer with different ferroptosis-related-scores

PROVIDER: PRJNA764173 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Next Generation Sequencing Facilitates Quantitative Analysis of Transcriptomes for advanced gastric cancer with different ferroptosis-related-scores

Project description:Gastric cancer is one of the leading causes of cancer mortality worldwide. We compared transcriptomic profiles of gastric cancer with different ferroptosis-related-scores to identify the prognostic significance of ferroptosis-related-score in gastric cancer.

2021-11-29 | GSE184336 | GEO

Next Generation Sequencing Facilitates Quantitative Analysis of Transcriptomes for advanced gastric cancer with different tumour-stroma-scores

Project description:Gastric cancer is one of the leading causes of cancer mortality worldwide. We compared transcriptomic profiles of advanced gastric cancer with different tumour-stroma-scores to identify the prognostic significance of tumour-stroma-score in advanced gastric cancer.

2021-11-29 | GSE179252 | GEO

Next Generation Sequencing Facilitates Quantitative Analysis of Transcriptomes for advanced gastric cancer with different tumour-stroma-scores

Project description:Next Generation Sequencing Facilitates Quantitative Analysis of Transcriptomes for advanced gastric cancer with different tumour-stroma-scores

| PRJNA743008 | ENA

Targeting SOX13 inhibits the assembly of respiratory chain supercomplexes to overcome ferroptosis-resistance in gastric cancer

Project description:Therapeutic resistance represents a bottleneck to treatment in advanced gastric cancer (GC). Ferroptosis is an iron-dependent form of non-apoptotic cell death and is associated with anti-cancer therapeutic efficacy. Further investigations are required to clarify the underlying mechanisms. Ferroptosis-resistant GC cell lines were constructed. Dysregulated mRNAs between ferroptosis-resistant and parental cell lines were identified. The expression of SOX13/SCAF1 was manipulated in GC cell lines where relevant biological and molecular analyses were performed. Molecular docking and computational screening were performed to screen potential inhibitors of SOX13. We showed that SOX13 boosts protein remodeling of electron transport chain (ETC) complexes by directly transactivating SCAF1. This leads to increased supercomplexes (SCs) assembly, mitochondrial respiration, mitochondrial energetics, NADPH production and chemo- and immune-resistance. Zanamivir, reverted the ferroptosis-resistant phenotype via directly targeting SOX13 and promoting TRIM25-mediated ubiquitination and degradation of SOX13. Overall, SOX13/SCAF1 are important in ferroptosis-resistance, and targeting SOX13 with zanamivir has therapeutic potential.

2023-11-17 | GSE247870 | GEO

Early and advanced gastric cancer genomes

2014-06-30 | GSE57176 | GEO

Early and advanced gastric cancer genomes

Project description:Early gastric cancers (EGC) precede advanced gastric cancers (AGC) with a favorable clinical outcome compared to advanced gastric cancers (AGC). To understand the progression mechanisms of EGC to AGC, it is required to disclose the EGC and AGC genomes in terms of the the mutational and evolutionary perspectives. In this study, we performed whole-exome sequencing and copy number profiling of nine microsatellite (MS)-unstable (MSI-H) (5 EGC and 4 AGC) and eight MS-stable (MSS) gastric cancers (4 EGC and 4 AGC). Unexpectedly, we observed no substantial differences in the number, sequence composition and functional consequences (potential driver mutations and affected pathways) of the mutations and CNAs between EGC and AGC genomes in both MSI-H and MSS cases. Gastrectomy tissues from 17 GC patients were used for this study. The hospital pathology department confirmed pathologic features of the GC (e.g., EGC vs. AGC, differentiation, lymph node metastasis and TNM stage). All of the picked areas from tumor and normal areas were frozen, cut, and stained with hematoxylin & eosin (H&E). Two pathologists selected cases with rich tumor cell population (at least 60%), which were subsequently used in the study. Copy number profiling was performed using Agilent 180K platform according to the manufacturer's protocol.

2014-06-30 | E-GEOD-57176 | biostudies-arrayexpress

Advanced Genome Sequencing Approaches in Gastric Cancer

Project description:Advanced Genome Sequencing Approaches in Gastric Cancer

| PRJNA384277 | ENA

Single cell RNA sequencing of advanced gastric cancer

Project description:Single cell RNA sequencing of advanced gastric cancer

| PRJNA588620 | ENA

FTO-dependent inhibition of ferroptosis in gastric cancer through epigenetic regulation of the HOXC8/MDM2/p53 signaling pathway

Project description:Only a few studies have attempted to explore the potential role of FTO in gastric cancer, with one focusing on mitochondrial metabolism, while others have focused on the association of FTO with cell proliferation, migration, and invasion. To date, no study has comprehensively linked FTO-dependent m6A methylation to any form of cell death. We comprehensively explore the role of FTO-mediated m6A modification in gastric cancer ferroptosis by MeRIP-seq.

2024-03-03 | GSE210623 | GEO

identification of differentially expressed Long Non-coding RNA profiles in advanced gastric cancer

Project description:Long non-coding RNAs (lncRNAs) may contribute to tumorigenesis and cancer progression by regulating the gene in various cancers, including advanced gastric cancer (AGC). To investigate differentially expressed lncRNAs in AGC, we use whole transcriptome sequencing in 3 pairs of human gastric adenocarcinoma and the corresponding normal tissues.

2023-08-10 | GSE210909 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data